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Abstract
Background: The present study examines changes in body weight, fat mass, metabolic and
hormonal parameters in overweight and obese pre- and postmenopausal women who participated
in a weight loss intervention.
Methods: Seventy-two subjects were included in the analysis of this single arm study
(premenopausal: 22 women, age 43.7 ± 6.4 years, BMI 31.0 ± 2.4 kg/m2; postmenopausal: 50
women, age 58.2 ± 5.1 years, BMI 32.9 ± 3.7 kg/m2). Weight reduction was achieved by the use of
a meal replacement and fat-reduced diet. In addition, from week 6 to 24 participants attended a
guided exercise program. Body composition was analyzed with the Bod Pod®. Blood pressures
were taken at every visit and blood was collected at baseline and closeout of the study to evaluate
lipids, insulin, cortisol and leptin levels.
Results: BMI, fat mass, waist circumference, systolic blood pressure, triglycerides, glucose, leptin
and cortisol were higher in the postmenopausal women at baseline.
Both groups achieved a substantial and comparable weight loss (pre- vs. postmenopausal: 6.7 ± 4.9
vs 6.7 ± 4.4 kg; n.s.). However, in contrast to premenopausal women, weight loss in
postmenopausal women was exclusively due to a reduction of fat mass (-5.3 ± 5.1 vs -6.6 ± 4.1 kg;
p < 0.01). In premenopausal women 21% of weight loss was attributed to a reduction in lean body
mass.
Blood pressure, triglycerides, HDL-cholesterol, and glucose improved significantly only in
postmenopausal women whereas total cholesterol and LDL-cholesterol were lowered significantly
in both groups.
Conclusion: Both groups showed comparable weight loss and in postmenopausal women weight
loss was associated with a pronounced improvement in metabolic risk factors thereby reducing the
prevalence of metabolic syndrome.
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The NHANES III surveys, conducted from 1988–1994,
have provided evidence that more than 50 % of women in
the United States are overweight or obese [1]. Although
the reasons for overweight and obesity in women are mul-
tilayered, it is well established that menopause is associ-
ated with weight gain and an unfavourable alteration in
body composition [2,3]. The risk for atherothrombotic
diseases in women increases after menopause. Several
investigations have demonstrated that deposition of vis-
ceral adipose fat is elevated in the postmenopausal state
[4]. Visceral fat accumulation has been associated with
increased metabolic risk factors and hence an increase in
cardiovascular diseases [5,6]. Therefore, successful strate-
gies for reducing overweight and improving metabolic
risk factors in women, particularly after menopause, are of
utmost importance.
There is widespread consensus that lifestyle changes
focused on improving dietary intake and increased daily
physical activities, are the cornerstones in both prevention
and treatment of obesity and the metabolic syndrome [7-
9].
Most recently, the results of the Women's Health Initiative
Trial including 48.835 postmenopausal women aged 50–
79 (mean follow-up 8.1 years) were published [10]. The
results show that an intensive diet modification program
together with individual counselling sessions to reduce fat
intake to 20 % of calories and to increase the intakes of
vegetables and fruits, did not significantly reduce clinical
endpoints for cardiovascular disease or stroke [11].
Weight loss was not part of the intervention and cardio-
vascular risk factors were rather modest. As the alterations
in CVD risk factors were modest, the authors concluded
that a more focused intervention of dietary and lifestyle
factors may be needed to improve cardiovascular risk fac-
tors and to reduce the incidence of cardiovascular disease.
In the present study we investigated the combined effects
of a weight loss regimen utilizing a meal replacement
(soy-yoghurt-honey preparation) and a guided physical
activity program on anthropometric measures and meta-
bolic risk factors in pre- and postmenopausal women. In
contrast to other studies published so far, we investigated
whether such an intervention would produce different
results in pre- versus postmenopausal women.
Methods
Seventy-six women were enrolled in this 12 month inter-
vention. Inclusion criteria: Female gender, age between 18
and 75 years, BMI between 27 and 35 and absence of con-
traindications to exercise. All subjects completed a com-
prehensive medical examination and routine blood tests.
Subjects were excluded if they had diabetes mellitus type
II, taking lipid-lowering drugs or medications that
affected body weight. 22 participants were pre-menopau-
sal, 50 were classified postmenopausal. Classification of
menopause was performed by anamnesis and analysis of
LH, FSH and estradiol. If FSH and LH were higher than 20
IU/ml and estradiol < 30 pmol/l, participants were classi-
fied as postmenopausal. Metabolic syndrome was diag-
nosed according to the NCEP ATP III criteria [12].
Written informed consent was given by all subjects; the
study protocol was approved by the ethical committee of
the University of Freiburg.
The study was divided into two phases; the first 6 month
was designated as the active intensive intervention period
where subjects had to change their dietary behaviour and
increase physical activity. In the following 6 month partic-
ipants were encouraged to continue these lifestyle changes
however they did so without study staff supervision.
Diet
Subjects were instructed to replace two daily meals with
soy-yoghurt honey drink (Almased® : amount per serving:
calories 180 kcal, total fat 1.5 g, carbohydrates 16 g, pro-
tein 25 g, cholesterol 0 g) for the first 6 weeks, followed by
the replacement of one daily meal for the next 18 weeks.
After this period, subjects were free to use the meal
replacement for the rest of the study. During the study,
participants were instructed to limit fat intake to not
exceed 60 g/d. Subjects were instructed during two face-to
face counseling sessions and were given educational pam-
phlets further detailing how to improve dietary behav-
iour. The regimen contained about 1000 kcal/d during the
first 6 weeks and 1500 kcal/d for the next 18 weeks. Par-
ticipants monitored their dietary intake using 3-day food
records at the beginning of the study and at 3 and 6
months.
Physical activity
Subjects attended twice weekly 60 minute endurance
physical activity sessions during the first six months. The
activity sessions were supervised by a trained exercise
counsellor and lasted for 6 months. Compliance was
assessed by participant attendance at the sessions. Adher-
ence was good as participants attended more than 80% of
the sessions. The training program consisted of mainly
aerobic or endurance type activities such as pulse-control-
led walking and team sports.
Data collected at baseline and 12 months were body
weight, fat mass, fat free mass, hip and waist circumfer-
ence, blood pressure and blood collection for serum lip-
ids, plasma glucose, insulin, leptin, cortisol and C-reactive
protein.Page 2 of 7
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Height was measured while subjects were barefoot.
Weight was measured using a digital scale, with the partic-
ipants wearing light clothing or underwear, and was
recorded to the nearest 0.01 kg. BMI was calculated as
weight divided by height squared (kg/m2). Waist circum-
ference was measured at the level midway between the
lowest rib margin and the iliac crest to the nearest 0.5 cm.
For body composition, the technique of the air displace-
ment plethysmography was used (Bod Pod®) [13].
Clinical measurements
Blood pressure was measured three times in the right arm
in the sitting position using a standard mercury sphyg-
momanometer, with at least 5 minutes rest between meas-
urements. Korotkoff's phases I and V sounds were
recorded for systolic (BPsys) and diastolic (BPdia) blood
pressure, respectively.
Serum analyses
Cortisol, Insulin and Leptin were measured by commer-
cially availably ELISA-tests (DSL Deutschland GmbH, Sin-
sheim, Germany). All other laboratory analyses were done
in the central laboratory of the University hospital using
clinical routine methods.
Statistical methods
Normality of all variables was tested before statistical
analyses using the Kolmogorov-Smirnov test procedure.
Testing for changes between examination at baseline and
at examination after 48 weeks was done by paired sample
T-test. The two sample T-test was used to establish signifi-
cant differences between the two groups at both examina-
tions. All P values were two-sided and a P value of 0.05 or
less was considered to indicate statistical significance.
Analysis was conducted with the use of SPSS software
(version 13.0).
Results
A total of 72 subjects (age 53 ± 9 y; weight 86.6 ± 10.3 kg;
BMI 32.3 ± 3.4 kg/m2,) completed the 12 month study.
Participant dropout (n = 4) was not associated with side
effects or adverse events. The descriptive characteristics of
the subjects at baseline and 48 weeks are summarized in
Table 1 and 2.
Anthropometric measurements
Weight loss was significant in both groups (premenopau-
sal: -6.7 ± 4.9 kg, p < 0.001; postmenopausal: -6.7 ± 4.4 kg
p < 0.001; Table 1) and comparable (Figure 1). At base-
line, BMI, fat mass and waist circumference were signifi-
cantly higher in postmenopausal women, whereas fat free
mass was significantly lower compared to premenopausal
women. In premenopausal women, most of the weight
loss was due to a reduction of fat mass. 1.4 ± 1.2 kg of
body weight reduction in premenopausal women and 0.1
± 1.0 kg in postmenopausal women was lost due to a
reduction of fat free mass (Table 1). The difference in
change in lean body mass was statistically significant
between the two groups (p < 0.01). Waist and hip circum-
ferences were significantly reduced in both groups (p <
0.01 for both parameters and groups).
At baseline, systolic (BPsys) blood pressure was signifi-
cantly higher in postmenopausal women (135 ± 12 to 146
± 18 mmHg, p < 0.05), whereas diastolic blood pressure
(BPdia) did not differ significantly. Improvement of BPsys
only reached statistical significance (-11.3 mmHg, p <
0.001 to baseline) in postmenopausal females. Changes
in BPsys and BPdia were comparable at the end of the
study between the groups.
Metabolic risk factors
At closeout, total cholesterol (TC) (-22.9 ± 25.5 mg/dl; p
< 0.01) and LDL-cholesterol (LDL-C) (-21.5 ± 19.27 mg/
dl; p < 0.01) were markedly lower in the premenopausal
Table 1: Individual and Anthropometric characteristics of subjects
Premenopausal women (n = 22) Postmenopausal women (n = 50)
Variable Baseline
Mean ± SD
48 weeks
Mean ± SD
Baseline
Mean ± SD
48 weeks
Mean ± SD
Age (years) 43.7 ± 6.4a 58.2 ± 5.1a
Height (cm) 166 ± 6 163 ± 6
Weight (kg) 85.5 ± 8.6 78.8 ± 9.7§ 87.1 ± 11.1 80.4 ± 10.7§
BMI (kg/m2) 31.0 ± 2.4a 28.6 ± 3.1§ 32.9 ± 3.7a 30.3 ± 3.7§
Waist circumference (cm) 99 ± 7a 92 ± 9a§ 104 ± 9 98 ± 10a§
Hip circumference (cm) 112 ± 6 106 ± 10§ 116 ± 8a 111 ± 8§
Fat mass (kg) 37.4 ± 6.9a 32.0 ± 9.0§ 42.5 ± 8.6a 35.9 ± 8.3§
Fat free mass (kg) 48.2 ± 4.6b 46.7 ± 4.5§ 44.6 ± 5.1b 44.5 ± 5.2
a = p < .05 between groups b = p < .01 between groups.
§ = p < .01 within groupsPage 3 of 7
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women (TC: -8.8 ± 30,7; p < 0.05; LDL-C: -6.6 ± 25.4 mg/
dl, p < 0.05). HDL-cholesterol (HDL-C) (+3.43 ± 11.7
mg/dl; p < 0.05), TG (-30.4 ± 53.7 mg/dl; p < 0.01) and
fasting glucose levels (Gluc) (-2.6 ± 9.3 mg/dl; p < 0.05)
improved significantly only in postmenopausal women.
The reductions in TC, TG and Gluc were not significantly
different between the groups (Figure 2), however the level
for each parameter was still significantly lower in the pre-
menopausal group at the end of the study (p < 0.05).
At the beginning of the study, 5 of 22 premenopausal
women fulfilled the criteria of the metabolic syndrome
compared to 21 of 50 postmenopausal women. After the
intervention, 4 premenopausal and 8 postmenopausal
women remained classified as having metabolic syn-
drome. The reduction of metabolic syndrome in postmen-
opausal women was statistically significant (p < 0.01).
Hormones
Post intervention levels of insulin, leptin, cortisol
improved significantly in the postmenopausal partici-
pants.
Insulin did not change significantly during the study in
premenopausal women. Cortisol was significantly higher
in postmenopausal women (17.7 ± 7.7 vs 22.1 ± 9.0 ng/
ml) at the beginning of the study (p < 0.02 between
groups) and showed a marked 18% decrease during the
study (p = 0.01) (Figure 3). In premenopausal women
cortisol levels did not change significantly. Leptin was
Comparison of changes after 48 weeks of total cholesterol (∆TC), triglycerides (∆TG), HDL-cholester l (∆HDL-C), LDL-cholesterol (∆LDL-C systolic (∆BPsys) nd diastolic BPdia) blood pr ssure and fasting serum g ucose (∆Glu ) between pre- an  postme op usal womenFigur  2
Comparison of changes after 48 weeks of total cholesterol 
(∆TC), triglycerides (∆TG), HDL-cholesterol (∆HDL-C), 
LDL-cholesterol (∆LDL-C), systolic (∆BPsys) and diastolic 
(∆BPdia) blood pressure and fasting serum glucose (∆Gluc) 
between pre- and postmenopausal women. * significant 
changes from baseline within group p < 0.05. ** significant 
changes from baseline within group p < 0.01.
-100
-80
-60
-40
-20
0
20
∆Chol ∆TG
∆HDL
∆LDL ∆Glc ∆BP
sys
∆BP
dia
m
g
/d
l
-100
-80
-60
-40
-20
0
20
premenopausal
postmenopausalm
m
H
g
n.s.
n.s.
p<0.05
n.s.
n.s.
n.s.
n.s.









Table 2: Cardiovascular risk factors of subjects
Premenopausal women (n = 22) Postmenopausal women (n = 50)
Variable Baseline
Mean± SD
48 weeks
Mean ± SD
Baseline
Mean ± SD
48 weeks
Mean ± SD
Total cholesterol (mg/dl) 223 ± 39 201 ± 37b§ 234 ± 40 225 ± 36b#
Triglycerides (mg/dl) 115 ± 44a 101 ± 41a 163 ± 101a 134 ± 74a§
HDL-cholesterol (mg/dl) 66.4 ± 13,7a 69.6 ± 15.3 60.7 ± 14.9a 63.9 ± 13.2#
LDL-cholesterol (mg/dl) 124.0 ± 21.1 102.6 ± 24.8b§ 131.2 ± 29.1 124.8 ± 27.0b#
Systolic BP (mmHg) 134 ± 12a 130 ± 15 146 ± 18a 135 ± 14§
Diastolic BP (mmHg) 86 ± 8 84 ± 7 89 ± 8 84 ± 8§
Glucose (mg/dl) 92 ± 14a 88 ± 11a 97 ± 12a 94 ± 11a#
Insulin (µU/ml) 9.7 ± 5.8 9.7 ± 9.8 9.6 ± 7.9 7.5 ± 7.0#
Cortisol (µg/dl) 17.7 ± 7.7a 15.4 ± 4.1a 22.1 ± 9.0a 18.0 ± 6.2a§
Leptin (ng/ml) 47.6 ± 15.5a 38.3 ± 15.9§ 63.6 ± 27.0a 45.9 ± 22.4§
a = p < .05 between groups b = p < .01 between groups.
# = p < .05 within groups § = p < .01 within groups
Comparison of changes after 48 weeks of body weight (∆bw), fat mass (∆fm), fat-free mass (∆ffm), waist (∆waist) and hip (∆hip) circumferenc bet n pre- and postmeno-pausal wo enFigure 1
Comparison of changes after 48 weeks of body weight 
(∆bw), fat mass (∆fm), fat-free mass (∆ffm), waist (∆waist) 
and hip (∆hip) circumference between pre- and postmeno-
pausal women. * significant changes from baseline within 
group p < 0.05. ** significant changes from baseline within 
group p < 0.01.
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ning (p < 0.02). In both groups the leptin level was signif-
icantly reduced (premenopausal: -9.3 ± 12.7 ng/ml; p <
0.01; postmenopausal: -18.1 ± 18.9 ng/ml; p < 0.01),
however the difference of reduction between the two
groups was not statistically significant.
Dietary intake data were collected by a self-reported 24-
hour recall and a dietary record for 3 days at the beginning
and after 3 and 6 months. Qualitative assessment of food
records indicated that most subjects complied with the
dietary program. However, dietary records revealed a con-
siderable underreporting of the caloric intake compared
to the achieved weight loss. The discrepancy was in such a
way that the results of the dietary records were not consid-
ered in the analysis.
Discussion
We found that the 12 month weight loss intervention uti-
lizing meal replacements and dietary counselling to
reduce dietary fat intake and increasing physical activity
led to substantial and significant favourable reductions in
anthropometric and metabolic risk factors in both pre-
and postmenopausal women.
The amount of weight loss in both groups was similar to
other reported findings in premenopausal [14-16] and
postmenopausal [17-20] women following comprehen-
sive lifestyle interventions. The results further demon-
strate that despite comparable weight loss, the
intervention was associated with a considerably higher
reduction in metabolic risk factors in postmenopausal
women compared to premenopausal women.
In both groups the reduction of body weight was mainly
due to a reduction in fat mass. In premenopausal women
loss of fat free mass accounted for 21% of the total weight
reduction, whereas in postmenopausal women the loss of
muscle mass was rather small (< 3% of weight loss). This
is encouraging as it demonstrates that weight reduction
using this type of intervention in postmenopausal women
is feasible without significantly reducing lean body mass.
In the context of weight loss, the preservation of muscle
mass is particularly important for maintenance of motor
competence and metabolic capacity of skeletal muscles.
Additionally, we have shown this to be true in a previous
study. In this intervention study we found that through
the use of a meal replacement (supply of high quality pro-
teins) and adequate physical activity regimen significant
weight reduction may be reached without losing muscle
mass. [21].
Fat mass and waist circumference were higher in postmen-
opausal women at the beginning of the study. This is in
accordance with previous findings showing that weight
gain during aging occurs predominantly in the abdominal
region [22,23]. Furthermore, it is known that after meno-
pause, waist circumference and visceral adipose tissue
accumulation increase beyond the effect of ageing [24]. In
our study, postmenopausal women exhibited a lower
reduction of waist circumference compared to premeno-
pausal women. This is in contrast to other studies employ-
ing regional analysis of body composition showing that
abdominal fat and thigh fat were the regions most signif-
icantly affected by weight loss in postmenopausal women
[25]. However, methods applied in this study do not
allow a further discrimination between different fat
regions.
Nevertheless, there is accumulating knowledge that fat
mass as well as the relation between muscle mass and fat
mass are associated with the expression of metabolic and
cardiovascular risk factors [26,27]. In our study, postmen-
opausal women showed higher initial levels of systolic
(BPsys) and diastolic blood pressure (BPdia), total choles-
terol (TC), LDL-cholesterol (LDL-C), triglycerides (TG)
plasma glucose (Gluc) and lower levels of HDL-Choles-
terol (HDL-C). However, only differences for BPsys, TG
and Gluc were significant. This underscores that the post-
menopausal women investigated showed a considerable
higher metabolic risk profile as presented in the NCEP
ATP III criteria [28]. After participating in the interven-
tion, the percentage of postmenopausal women with the
metabolic syndrome was reduced from 42 to 16% (p <
0.01) compared to a non-significant decrease from 23 to
18% in premenopausal women. The significant reduction
in the prevalence of the metabolic syndrome in postmen-
opausal women demonstrates that despite a relatively
smaller reduction in waist circumference and fat mass, the
Comparison of changes after 48 weeks in Insulin (∆Insulin), Leptin (∆Leptin) and Cortisol (∆Corti ol) between pre- and pos menopausal womenFigur  3
Comparison of changes after 48 weeks in Insulin (∆Insulin), 
Leptin (∆Leptin) and Cortisol (∆Cortisol) between pre- and 
postmenopausal women. Cortisol levels were divided by 10. 
*significant changes from baseline within group p < 0.05. ** 
significant changes from baseline within group p < 0.01.
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menopausal women with respect to the reduction in met-
abolic risk factors.
However, our data also show that premenopausal women
experienced a significant reduction in cardiovascular risk
factors. Elevated fasting levels of plasma insulin and
impaired glucose tolerance have been widely recognized
as major independent risk factors for the development of
coronary heart disease [29]. In both groups, fasting blood
glucose was reduced. However, the reduction in insulin
levels was only significant in the postmenopausal women.
As insulin levels or insulin sensitivity have shown to be
correlated to abdominal fat mass [30], the decrease in
insulin in postmenopausal women may be explained by
the higher reduction of fat mass in this group.
The same differences were detected for cortisol, one of the
counterparts of insulin action. Our results confirm the
finding that higher levels of adiposity are associated with
higher concentrations of serum leptin [31]. Leptin levels
were significantly reduced by reduction of fat mass in
both groups. Despite a higher absolute reduction of fat
mass in postmenopausal women, the proportion of fat
mass remained higher in postmenopausal women at the
end of the study. Therefore, postinterventional Leptin lev-
els were still higher in postmenopausal women.
Doucet et al. described that during weight reduction the
decrease in fasting plasma insulin was the only significant
correlate of changes in fasting plasma leptin levels [32]. In
our study, reduction of insulin, leptin and cortisol was
severalfold higher in the postmenopausal group.
Weight loss programs including pharmaceutical interven-
tions have shown to be associated with considerable
higher drop-out rates [33]. In our study, the weight loss
intervention was very well accepted by all participants as
shown by the low drop-out rate. In an evaluation partici-
pants appreciated the personal counselling and the
guided activity program as very helpful.
Conclusion
The results demonstrate that the intervention, consisting
of meal replacement beverage, additional dietary counsel-
ling and guided physical activity sessions, was associated
with considerable weight loss in both premenopausal and
postmenopausal women. In addition, after the interven-
tion, metabolic risk factors in women were decisively
lower; indicating the usefulness of this lifestyle approach
to reduce both metabolic syndrome and risk factors for
cardiovascular disease in women.
Abbreviations
ATP Adult treatment panel
BMI body mass index
BPsys systolic blood pressure
BPdia diastolic blood pressure
Gluc blood glucose
HDL-C high density lipoprotein cholesterol
LDL-C low density lipoprotein cholesterol
NHANES National Health and Nutrition Examination
Survey
TC total cholesterol
TG triglycerides
Competing interests
Aloys Berg has received grants from Almased Wellness
Corporation. The other authors declare that they have no
competing interests.
Authors' contributions
Aloys Berg was the principal investigator of the study.
Peter Deibert and Daniel König were involved in the
design and execution of the study and performed the sta-
tistical analysis. Ulrike Landmann and Ingrid Frey per-
formed the diet counselling and physical training of the
participants. Mara Z Vitolins and Hans-Peter Zahradnik
contributed to data interpretation and manuscript prepa-
ration. All authors read and approved the final manu-
script.
Acknowledgements
Part of the costs were coped by Almased Wellness Corporation. The plan-
ning, organisation, monitoring and analysis of the study were performed 
independently.
References
1. Executive Summary of The Third Report of The National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, And Treatment of High Blood Cho-
lesterol In Adults (Adult Treatment Panel III).  JAMA 2001,
285:2486-2497.
2. Astrup A: Physical activity and weight gain and fat distribution
changes with menopause: current evidence and research
issues.  Med Sci Sports Exerc 1999, 31:S564-S567.
3. Tchernof A, Poehlman ET: Effects of the menopause transition
on body fatness and body fat distribution.  Obesity Res 1998,
6:246-254.
4. Faria AN, Ribeiro Filho FF, Gouveia F Sr, Zanella MT: Impact of vis-
ceral fat on blood pressure and insulin sensitivity in hyper-
tensive obese women.  Obes Res 2002, 10:1203-1206.
5. Hernandez-Ono A, Monter-Carreola G, Zamora-Gonzalez J, Car-
doso-Saldana G, Posadas-Sanchez R, Torres-Tamayo M, Posadas-
Romero C: Association of visceral fat with coronary risk fac-
tors in a population-based sample of postmenopausal
women.  Int J Obes Relat Metab Disord 2002, 26:33-39.Page 6 of 7
(page number not for citation purposes)
Nutrition Journal 2007, 6:31 http://www.nutritionj.com/content/6/1/31Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
6. You T, Ryan AS, Nicklas BJ: The metabolic syndrome in obese
postmenopausal women: relationship to body composition,
visceral fat, and inflammation.  J Clin Endocrinol Metab 2004,
89:5517-5522.
7. Deedwania PC, Volkova N: Current Treatment Options for the
Metabolic Syndrome.  Curr Treat Options Cardiovasc Med 2005,
7:61-74.
8. Ernst ND, Cleeman JI: National cholesterol education program
keeps a priority on lifestyle modification to decrease cardio-
vascular disease risk.  Curr Opin Lipidol 2002, 13:69-73.
9. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi
RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride
P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn
VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr,
Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL: Evi-
dence-based guidelines for cardiovascular disease preven-
tion in women.  Circulation 2004, 109:672-693.
10. Howard BV, Manson JE, Stefanick ML, Beresford SA, Frank G, Jones
B, Rodabough RJ, Snetselaar L, Thomson C, Tinker L, Vitolins M,
Prentice R: Low-fat dietary pattern and weight change over 7
years: the Women's Health Initiative Dietary Modification
Trial.  JAMA 2006, 295:39-49.
11. Howard BV, Manson JE, Stefanick ML, Beresford SA, Frank G, Jones
B, Rodabough RJ, Snetselaar L, Thomson C, Tinker L, Vitolins M,
Prentice R: Low-fat dietary pattern and weight change over 7
years: the Women's Health Initiative Dietary Modification
Trial.  JAMA 2006, 295:39-49.
12. Executive Summary of The Third Report of The National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, And Treatment of High Blood Cho-
lesterol In Adults (Adult Treatment Panel III).  JAMA 2001,
285:2486-2497.
13. McCrory MA, Gomez TD, Bernauer EM, Mole PA: Evaluation of a
new air displacement plethysmograph for measuring human
body composition.  Med Sci Sports Exerc 1995, 27:1686-1691.
14. Hackman RM, Havel PJ, Schwartz HJ, Rutledge JC, Watnik MR, Noceti
EM, Stohs SJ, Stern JS, Keen CL: Multinutrient supplement con-
taining ephedra and caffeine causes weight loss and
improves metabolic risk factors in obese women: a rand-
omized controlled trial.  Int J Obes (Lond) 2006.
15. Mougios V, Kazaki M, Christoulas K, Ziogas G, Petridou A: Does the
intensity of an exercise programme modulate body compo-
sition changes?  Int J Sports Med 2006, 27:178-181.
16. Lofgren IE, Herron KL, West KL, Zern TL, Brownbill RA, Ilich JZ, Koo
SI, Fernandez ML: Weight loss favorably modifies anthropo-
metrics and reverses the metabolic syndrome in premeno-
pausal women.  J Am Coll Nutr 2005, 24:486-493.
17. You T, Berman DM, Ryan AS, Nicklas BJ: Effects of hypocaloric
diet and exercise training on inflammation and adipocyte
lipolysis in obese postmenopausal women.  J Clin Endocrinol
Metab 2004, 89:1739-1746.
18. Berman DM, Nicklas BJ, Ryan AS, Rogus EM, Dennis KE, Goldberg AP:
Regulation of lipolysis and lipoprotein lipase after weight loss
in obese, postmenopausal women.  Obes Res 2004, 12:32-39.
19. Cordero-Macintyre ZR, Peters W, Libanati CR, Espana RC, Howell
WH, Lohman TG: Effect of a weight-reduction program on
total and regional body composition in obese postmenopau-
sal women.  Ann N Y Acad Sci 2000, 904:526-535.
20. Carels RA, Darby LA, Cacciapaglia HM, Douglass OM: Reducing
cardiovascular risk factors in postmenopausal women
through a lifestyle change intervention.  J Womens Health
(Larchmt) 2004, 13:412-426.
21. Deibert P, König D, Schmidt-Trucksaess A, Zaenker KS, Frey I, Land-
mann U, Berg A: Weight loss without losing muscle mass in
pre-obese and obese subjects induced by a high-soy-protein
diet.  Int J Obes Relat Metab Disord 2004, 28:1349-1352.
22. Ley CJ, Lees B, Stevenson JC: Sex- and menopause-associated
changes in body-fat distribution.  Am J Clin Nutr 1992,
55:950-954.
23. Haarbo J, Marslew U, Gotfredsen A, Christiansen C: Postmenopau-
sal hormone replacement therapy prevents central distribu-
tion of body fat after menopause.  Metabolism 1991,
40:1323-1326.
24. Kuk JL, Lee S, Heymsfield SB, Ross R: Waist circumference and
abdominal adipose tissue distribution: influence of age and
sex.  Am J Clin Nutr 2005, 81:1330-1334.
25. Cordero-Macintyre ZR, Peters W, Libanati CR, Espana RC, Howell
WH, Lohman TG: Effect of a weight-reduction program on
total and regional body composition in obese postmenopau-
sal women.  Ann N Y Acad Sci 2000, 904:526-535.
26. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L:
Distribution of adipose tissue and risk of cardiovascular dis-
ease and death: a 12 year follow up of participants in the pop-
ulation study of women in Gothenburg, Sweden.  Br Med J
1984, 289:1257-1261.
27. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin
G: Abdominal adipose tissue distribution, obesity, and risk of
cardiovascular disease and death: 13 year follow up of partic-
ipants in the study of men born in 1913.  Br Med J 1984,
288:1401-1404.
28. Executive Summary of The Third Report of The National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, And Treatment of High Blood Cho-
lesterol In Adults (Adult Treatment Panel III).  JAMA 2001,
285:2486-2497.
29. Mykkanen L, Laakso M, Pyorala K: High plasma insulin level asso-
ciated with coronary heart disease in the elderly.  Am J Epide-
miol 1993, 137:1190-1202.
30. Ouyang P, Sung J, Kelemen MD, Hees PS, DeRegis JR, Turner KL,
Bacher AC, Stewart KJ: Relationships of insulin sensitivity with
fatness and fitness and in older men and women.  J Womens
Health (Larchmt) 2004, 13:177-185.
31. Mahabir S, Baer D, Johnson LL, Roth M, Campbell W, Clevidence B,
Taylor PR: Body Mass Index, percent body fat, and regional
body fat distribution in relation to leptin concentrations in
healthy, non-smoking postmenopausal women in a feeding
study.  Nutr J 2007, 6:3.
32. Doucet E, St Pierre S, Almeras N, Mauriege P, Despres JP, Richard D,
Bouchard C, Tremblay A: Fasting Insulin Levels Influence
Plasma Leptin Levels Independently from the Contribution
of Adiposity: Evidence from Both a Cross-Sectional and an
Intervention Study.  J Clin Endocrinol Metab 2000, 85:4231-4237.
33. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect
of rimonabant, a cannabinoid-1 receptor blocker, on weight
and cardiometabolic risk factors in overweight or obese
patients: RIO-North America: a randomized controlled trial.
JAMA 2006, 295:761-775.Page 7 of 7
(page number not for citation purposes)
